Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
In the latest session, Generation Bio Co (NASDAQ: GBIO) closed at $0.3 down -15.40% from its previous closing price of $0.36. In other words, the price has decreased by -$15.40 from its previous closing price. On the day, 7.36 million shares were traded. GBIO stock price reached its highest trading level at $0.37 during the session, while it also had its lowest trading level at $0.3004.
Ratios:
For a deeper understanding of Generation Bio Co’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.43 and its Current Ratio is at 8.43. In the meantime, Its Debt-to-Equity ratio is 1.19 whereas as Long-Term Debt/Eq ratio is at 1.07.
On November 08, 2022, Canaccord Genuity started tracking the stock assigning a Buy rating and target price of $9.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jan 10 ’25 when Quinn Anthony G. bought 125,791 shares for $0.96 per share. The transaction valued at 120,759 led to the insider holds 214,286 shares of the business.
Quinn Anthony G. bought 85,000 shares of GBIO for $82,450 on Jan 13 ’25. The Director now owns 299,286 shares after completing the transaction at $0.97 per share. On Jul 01 ’24, another insider, Paone Antoinette, who serves as the CHIEF OPERATING OFFICER of the company, sold 6,719 shares for $2.74 each. As a result, the insider received 18,410 and left with 13,807 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GBIO now has a Market Capitalization of 20137374 and an Enterprise Value of -49844616. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.82 while its Price-to-Book (P/B) ratio in mrq is 0.27. Its current Enterprise Value per Revenue stands at -2.03 whereas that against EBITDA is 0.72.
Stock Price History:
The Beta on a monthly basis for GBIO is 2.64, which has changed by -0.8832685 over the last 52 weeks, in comparison to a change of 0.12748289 over the same period for the S&P500. Over the past 52 weeks, GBIO has reached a high of $3.65, while it has fallen to a 52-week low of $0.32. The 50-Day Moving Average of the stock is -22.98%, while the 200-Day Moving Average is calculated to be -72.50%.
Shares Statistics:
For the past three months, GBIO has traded an average of 532.40K shares per day and 1188790 over the past ten days. A total of 67.01M shares are outstanding, with a floating share count of 45.82M. Insiders hold about 31.65% of the company’s shares, while institutions hold 54.54% stake in the company. Shares short for GBIO as of 1749772800 were 1881240 with a Short Ratio of 3.53, compared to 1747267200 on 1892299. Therefore, it implies a Short% of Shares Outstanding of 1881240 and a Short% of Float of 4.0900003.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The dynamic stock of Generation Bio Co (GBIO) is currently being evaluated by a team of 1.0 analysts, each contributing to its current rating.The consensus estimate for the next quarter is -$0.26, with high estimates of -$0.26 and low estimates of -$0.26.
Analysts are recommending an EPS of between -$0.97 and -$0.97 for the fiscal current year, implying an average EPS of -$0.97. EPS for the following year is -$0.75, with 3.0 analysts recommending between -$0.17 and -$1.26.
Revenue Estimates
A total of 5 analysts believe the company’s revenue will be $2.51M this quarter.It ranges from a high estimate of $4.1M to a low estimate of $155k. As of the current estimate, Generation Bio Co’s year-ago sales were $4.09MFor the next quarter, 5 analysts are estimating revenue of $2.49M. There is a high estimate of $4M for the next quarter, whereas the lowest estimate is $155k.
A total of 6 analysts have provided revenue estimates for GBIO’s current fiscal year. The highest revenue estimate was $20.8M, while the lowest revenue estimate was $8.7M, resulting in an average revenue estimate of $14.94M. In the same quarter a year ago, actual revenue was $19.89M
